NextCure Clinical data updates expected in 2023 for all three programs NC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML) Ended 2022 with approximately $160 million in cash that is expected to fund operations into mid-2025 BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE)… Read More..

KELOWNA, BC / ACCESSWIRE / March 2, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its diabetes animal model study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-conditioned animals, together… Read More..

Project Deployment and Recurring Revenue Generation Expected to Start in the Near Future TEL AVIV, Israel, March 1, 2023 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced it has launched a $3.6 million project with the national government of Finland… Read More..